Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program To Evaluate Automated Manufacturing Of CAR-T Cell Therapy On The Cell Shuttle Platform
Portfolio Pulse from Happy Mohamed
Cellares, a cell therapy manufacturing organization, announced that Bristol Myers Squibb (BMY) has joined its Technology Adoption Partnership (TAP) program. BMY will use Cellares' automated manufacturing platform, the Cell Shuttle, for a proof-of-concept transfer process for one of its CAR-T cell therapies. The TAP program allows cell therapy developers to adopt Cellares' automated manufacturing technology for their products. BMY aims to evaluate the automated manufacturing process and confirm the Cell Shuttle as a cost-efficient and scalable manufacturing solution for cell therapies.
August 28, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb has joined Cellares' TAP program to evaluate the automated manufacturing of its CAR-T cell therapy. This could potentially lower manufacturing costs and increase scalability for BMY's cell therapies.
Bristol Myers Squibb's partnership with Cellares could potentially lower the manufacturing costs and increase the scalability of its CAR-T cell therapies. This could lead to increased production and potentially higher revenues, which could positively impact BMY's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100